Cite
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors
MLA
Alejandro Zulbaran‐Rojas, et al. “A Prospective Analysis of Symptom Burden for Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Frontline Second‐ and Third‐generation Tyrosine Kinase Inhibitors.” Cancer Medicine, vol. 7, no. 11, Nov. 2018, pp. 5457–69. EBSCOhost, https://doi.org/10.1002/cam4.1808.
APA
Alejandro Zulbaran‐Rojas, Huei‐Kan Lin, Qiuling Shi, Loretta A. Williams, Binsah George, Guillermo Garcia‐Manero, Elias Jabbour, Susan O’Brien, Farhad Ravandi, William Wierda, Zeev Estrov, Gautam Borthakur, Tapan Kadia, Charles Cleeland, Jorge E. Cortes, & Hagop Kantarjian. (2018). A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors. Cancer Medicine, 7(11), 5457–5469. https://doi.org/10.1002/cam4.1808
Chicago
Alejandro Zulbaran‐Rojas, Huei‐Kan Lin, Qiuling Shi, Loretta A. Williams, Binsah George, Guillermo Garcia‐Manero, Elias Jabbour, et al. 2018. “A Prospective Analysis of Symptom Burden for Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Frontline Second‐ and Third‐generation Tyrosine Kinase Inhibitors.” Cancer Medicine 7 (11): 5457–69. doi:10.1002/cam4.1808.